Drugmakers Call for Clarification of FDA’s Postapproval Change Guidance

Drug Industry Daily
A A
Leading drug companies called for tweaks in the FDA’s draft guidance on postapproval changes for drugs to help clarify info and better align with ICH guidelines.

To View This Article:

Login

Subscribe To Drug Industry Daily